Phase 1/2Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRAScendo 170)
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 320 planned
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed
- Ages
- adults, older adults
- Registry
- NCT05789082
From the registry
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Primary outcomes
- Percentage of Participants with Adverse Events (AEs)